DOCSLIB.ORG

Doxepin for Insomnia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Doxepin for Insomnia Out of the Pipeline p Doxepin for insomnia Dimitri Markov, MD, and Karl Doghramji, MD ow-dose doxepin—3 mg and 6 mg— Table 1 Low-dose doxepin has demonstrated efficacy for insom- may relieve sleep Doxepin: Fast facts Lnia characterized by frequent or early- maintenance morning awakenings and an inability to Brand name: Silenor insomnia and is return to sleep (Table 1).1 FDA-approved in Indication: Insomnia characterized by difficulty not designated March 2010, doxepin (3 mg and 6 mg) is only with sleep maintenance as a controlled the second insomnia medication not des- Approval date: March 2010 ignated as a controlled substance and thus Availability date: September 7, 2010 substance may be of special value in patients with a Manufacturer: Somaxon Pharmaceuticals history of substance abuse. Dosage forms: 3 mg and 6 mg tablets Recommended dosage: 3 mg or 6 mg once Clinical implications daily within 30 minutes of bedtime Ramelteon, the other hypnotic that is not a controlled substance, is indicated for sleep initiation insomnia (ie, inability to fall How it works asleep). In contrast, low-dose doxepin is for Doxepin’s mechanism of action for treat- patients with sleep maintenance insomnia, ing depression and insomnia remains un- which is waking up frequently or early in known. The antidepressant effect of dox- the morning and not falling back asleep.1,2 epin is thought to result from inhibition A tricyclic antidepressant first approved of serotonin and norepinephrine reuptake in 1969, doxepin has long been available in at the synaptic cleft. Animal studies have larger doses (10-, 25-, 50-, 75-, 100-, and 150- shown anticholinergic and antihistamin- mg capsules) to treat depression and anxiety ergic activity with doxepin.2 Doxepin and as a topical preparation (5% cream) for is a potent histamine antagonist—pre- pruritus, but not in dosages <10 mg. An in- dominantly at the H1 receptor—and its expensive generic doxepin oral solution (10 binding potency to the H1 receptor is mg/ml) is available and can be titrated to approximately 100-times higher than its smaller dosages by a dropper. Liquid dox- binding potency for monoamine trans- epin costs 10 to 20 cents per dose. A phar- porters (serotonin and norepinephrine).2,3 macist can provide a dropper, and patients Brain histamine is believed to be 1 of the should mix the medication in 4 ounces of key elements in maintaining wakeful- water, milk, or juice; 0.3 ml of liquid doxepin ness, and the activation of the H1 recep- contains 3 mg of active ingredient and 0.6 ml of solution contains 6 mg of doxepin. These Dr. Markov is assistant professor of psychiatry and human behav- ior, assistant professor of medicine, Jefferson Medical College, other dosage forms of doxepin, however, are attending physician, Jefferson Sleep Disorders Center, Thomas Jef- not FDA-approved for insomnia. (The retail ferson University, and Dr. Doghramji is professor of psychiatry and human behavior, professor of medicine, professor of neurology, price of low-dose doxepin was not available Jefferson Medical College, and medical director, Jefferson Sleep Current Psychiatry when this article went to press.) Disorders Center, Thomas Jefferson University, Philadelphia, PA. Vol. 9, No. 10 67 Out of the Pipeline tor is thought to play an important role double the doxepin plasma concentra- in mediating arousal. Blockade of the H1 tion; therefore, patients taking cimetidine receptor by doxepin likely plays a role in should not exceed 3 mg/d of doxepin. reducing wakefulness. Typically, thera- peutic doses of antidepressants with anti- Efficacy histaminergic properties, such as doxepin Doxepin reduced insomnia symptoms in 3 at antidepressant doses, amitriptyline, pilot studies at doses of 10, 25, and 50 mg, or desipramine, do not selectively block and in 2 phase III randomized, double- H1 receptors, but act at cholinergic, sero- blind, placebo-controlled clinical trials us- tonergic, adrenergic, histaminergic, and ing 1, 3, and 6 mg (Table 2, page 74).4,5 Clini- muscarinic receptors, which can cause cal studies lasted up to 3 months.1-3,6-8 adverse effects.3 However, low doses of In the first phase III trial, 67 patients, age doxepin (1, 3, and 6 mg) can achieve se- 18 to 64 with chronic primary insomnia, lective H1 blockade.4,5 Patients taking >25 were randomly assigned to placebo or 1 Clinical Point mg/d of doxepin may report clinically mg, 3 mg, or 6 mg of doxepin for 2 nights. Blockade of the significant anticholinergic effects. All patients received all treatments, and H1 receptor by each treatment was followed by 8 hours Pharmacokinetics of polysomnography (PSG) evaluation in doxepin likely plays When doxepin, 6 mg, was administered a sleep laboratory.4 In this study, patients a role in reducing to healthy, fasting patients, time to maxi- taking doxepin at all doses achieved im- wakefulness mum concentration (Tmax) was 3.5 hours. provement in objective (PSG-defined) and Peak plasma concentration (Cmax) in- subjective (patient-reported) measures of creased in a dose-related fashion when sleep duration and sleep maintenance. doxepin was increased from 3 mg to 6 mg. Wake after sleep onset (WASO), total sleep Doxepin, 6 mg, taken with a high-fat meal time (TST), and sleep efficiency (SE) im- resulted in area under the curve increase proved with all doxepin doses, and wake of 41%, Cmax increase of 15%, and al- time during sleep (WTDS)—which was the most 3-hour delay in Tmax. Therefore, to primary study endpoint—decreased with prevent a delay in onset of action and to 3 mg and 6 mg doses, but not with 1 mg minimize the likelihood of daytime seda- or placebo. In addition, PSG indicators of tion, doxepin should not be taken within early-morning awakenings (terminal in- 3 hours of a meal.1-3 somnia) were reduced, as shown by an Doxepin is metabolized primarily by increase in SE during the final third of the the liver’s cytochrome P450 (CYP) 2C19 night and the 7th and 8th hours of sleep (1, 3, and CYP2D6 enzymes; CYP1A2 and and 6 mg doses) and a reduction in wake CYP2D6 are involved to a lesser extent. time after sleep (WTAS) during the final If doxepin is coadministered with drugs third of the night (6 mg only). The effects that inhibit these isoenzymes, such as on sleep duration and maintenance were fluoxetine and paroxetine, doxepin blood more robust with 3 mg and 6 mg doses. levels may increase. Doxepin does not Improved sleep onset was seen only with seem to induce CYP isoenzymes. This the 6 mg dose. Next-day alertness was as- medication is metabolized by demethyl- sessed using the Visual Analogue Scale ation and oxidation; the primary metabo- (VAS) for sleepiness, and the Digit-Symbol lite is nordoxepin (N-desmethyldoxepin), Substitution Test (DSST) and the Symbol- which later undergoes glucuronide conju- Copying Task (SCT) for psychomotor func- gation. The half-life is 15 hours for doxe- tion. No statistically significant differences pin and 31 hours for nordoxepin. Doxepin were found among placebo and any of the is excreted in urine primarily as glucuro- doxepin doses on the VAS, DSST, or SCT. nide conjugate.1-3 Doxepin was well tolerated. Reported Coadministration with cimetidine, adverse events were mild or moderate. Current Psychiatry 68 October 2010 an inhibitor of CYP isoenzymes, could Headaches and somnolence were report- continued on page 74 Out of the Pipeline continued from page 68 Table 2 Evidence of effectiveness of doxepin for insomnia Study Subjects Dosages Results Roth et al, 20074; 67 patients 1, 3, or 6 Improvement vs placebo in PSG-defined phase III, randomized, age 18 to 64 mg given WASO, TST, SE, and SE during the final third multi-center, double- with chronic once daily at of the night. 6-mg dose significantly reduced blind, placebo- primary bedtime for 2 subjective latency to sleep onset. Safety controlled, 4-period insomnia nights profile of all 3 doses was comparable to crossover, dose- placebo. No difference in residual sedation response study Scharf et al, 20085; 76 patients 1, 3, or 6 mg Reduction vs placebo in WTDS and WASO phase III, randomized, age ≥65 at bedtime for at all 3 doses. Increase in TST and SE at multi-center, double- with primary 2 nights all 3 doses. No difference in number of blind, placebo- insomnia awakenings after sleep onset and latency to controlled, 4-period persistent sleep at all 3 doses. WTAS was Clinical Point crossover, dose- reduced only at 3 and 6 mg doses. Patient- response study reported WTAS was decreased at all doses. Doxepin is better Patient-reported latency to sleep onset decreased only with 6 mg. Safety profile tolerated at hypnotic of all 3 doses was comparable to placebo doses than at and there were no differences among placebo and all 3 doses doxepin in next-day antidepressant doses, sleepiness or psychomotor function although direct PSG: polysomnography; SE: sleep efficiency; TST: total sleep time; WASO: wake after sleep onset; WTAS: wake time after sleep; WTDS: wake time during sleep comparative studies Source: References 4,5 are not available ed by >2% of patients. The incidence of insomnia patients with early morning adverse events, including next-day seda- awakenings. tion, was similar to that of placebo. Ad- In this study, no statistically significant ditionally, there were no spontaneous differences were found among placebo reports of anticholinergic side effects, and any doxepin doses on VAS, DSST, or which are associated with higher doxepin SCT or next-day residual sedation. The doses.4 incidence of side effects was low and The second phase III trial examined similar to that of placebo.
Load more

Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • Molecular Signatures of G-Protein-Coupled Receptors A
    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Drugs Inducing Insomnia As an Adverse Effect
    2 Drugs Inducing Insomnia as an Adverse Effect Ntambwe Malangu University of Limpopo, Medunsa Campus, School of Public Health, South Africa 1. Introduction Insomnia is a symptom, not a stand-alone disease. By definition, insomnia is "difficulty initiating or maintaining sleep, or both" or the perception of poor quality sleep (APA, 1994). As an adverse effect of medicines, it has been documented for several drugs. This chapter describes some drugs whose safety profile includes insomnia. In doing so, it discusses the mechanisms through which drug-induced insomnia occurs, the risk factors associated with its occurrence, and ends with some guidance on strategies to prevent and manage drug- induced insomnia. 2. How drugs induce insomnia There are several mechanisms involved in the induction of insomnia by drugs. Some drugs affects sleep negatively when being used, while others affect sleep and lead to insomnia when they are withdrawn. Drugs belonging to the first category include anticonvulsants, some antidepressants, steroids and central nervous stimulant drugs such amphetamine and caffeine. With regard to caffeine, the mechanism by which caffeine is able to promote wakefulness and insomnia has not been fully elucidated (Lieberman, 1992). However, it seems that, at the levels reached during normal consumption, caffeine exerts its action through antagonism of central adenosine receptors; thereby, it reduces physiologic sleepiness and enhances vigilance (Benington et al., 1993; Walsh et al., 1990; Rosenthal et al., 1991; Bonnet and Arand, 1994; Lorist et al., 1994). In contrast to caffeine, methamphetamine and methylphenidate produce wakefulness by increasing dopaminergic and noradrenergic neurotransmission (Gillman and Goodman, 1985). With regard to withdrawal, it may occur in 40% to 100% of patients treated chronically with benzodiazepines, and can persist for days or weeks following discontinuation.
    [Show full text]
  • SIGHI-Leaflet Histamine Elimination Diet Simplified Histamine Elimination Diet for Histamine Intolerance (DAO Degradation Disorder)
    Version 2020-07-20 SIGHI-Leaflet Histamine Elimination Diet Simplified histamine elimination diet for histamine intolerance (DAO degradation disorder) For people with a DAO degradation disorder The compatibility is highly dependent on the in- who have to avoid histamine, other biogenic dividual sensitivity and the amount consumed. amines and DAO inhibitors in their diet. Furthermore, it is temporarily affected by stress, In case of histamine sensitivity due to mast cell hormones and many other factors. First and activation disorders (MCAD) this dietary guide- foremost, the freshness is an important cri- line is not sufficient! If no permanent symptom terion. Everybody has to find out by trial and er- relief can be achieved and maintained with this ror what he/she can tolerate in what quantities. diet, please follow the detailed list, which addi- At the beginning of the experimental diet this list tionally takes histamine liberators into consid- should be followed as consistently as possible. eration as completely as possible. It is available In a later stage, however, the diet should be here: based more on the experiences of the person www.mastzellaktivierung.info concerned rather than following any list. Mast cell activation disorders are often mistaken Always read the list of ingredients to find out for histamine intolerance. whether a food contains incompatible ingredi- ents. References: • Experience reports from among our members and readers • Various patient leaflets from doctors, clinics and hospitals • Experience of other patient organizations, bloggers, forum threads etc. • Scientific publications • Textbooks and cookbooks about histamine intolerance To avoid: ? Risky: Well tolerated: Fermented or microbially ripened Meals from res- Prefer fresh, unprocessed or little pro- products (e.g.
    [Show full text]
  • Isoflurane Produces Antidepressant Effects and Induces Trkb Signaling in Rodents
    bioRxiv preprint doi: https://doi.org/10.1101/084525; this version posted July 11, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Isoflurane produces antidepressant effects and induces TrkB signaling in rodents Hanna Antilaa, Maria Ryazantsevaa,b, Dina Popovaa, Pia Sipiläa, Ramon Guiradoa, Samuel Kohtalaa,b, Ipek Yalcinc, Jesse Lindholma, Liisa Vesaa, Vinicius Satod, Joshua Cordeirae, Henri Autioa, Mikhail Kislina, Maribel Riose, Sâmia Jocad, Plinio Casarottoa, Leonard Khirouga, Sari Lauria,b, Tomi Tairaa,f, Eero Castréna* and Tomi Rantamäkia,b* aNeuroscience Center, P.O. Box 56, FI-00014 University of Helsinki, Helsinki, Finland. bDivision of Physiology and Neuroscience, Department of Biosciences, Faculty of Biological and Environmental Sciences, P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. cInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, FR-67084 Strasbourg Cedex, France. dSchool of Pharmaceutical Sciences of Ribeirão Preto 14040-903, Brazil. eTufts University, Boston, MA, USA. fDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. *To whom correspondence should be addressed at: Eero Castrén ([email protected]) or Tomi Rantamäki ([email protected]) A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β).
    [Show full text]
  • Sleep Inducing Toothpaste Made with Natural Herbs and a Natural Hormone
    Sleep inducing toothpaste made with natural herbs and a natural hormone Abstract A toothpaste composition for inducing sleep while simultaneously promoting intraoral cleanliness, which includes toothpaste base ingredients and at least one sleep- inducing natural herb or hormone. The sleep-inducing natural herbs and hormone are selected from the group consisting of Chamomile, Lemon Balm, Passion Flower, and Valerian, and the hormone Melatonin. The sleep-inducing natural herbs are in a range of 0.25% to 18% by weight of the composition. Description of the Invention FIELD OF THE INVENTION The following natural herbs and natural hormone in combination with toothpaste is used at night to improve sleep. The expected dose of toothpaste is calculated at 2 grams. The ingredients have been assessed for range of daily dose for best effects, toxicity in normal range, recommended proportion of each, and water solubility of key constituents. BACKGROUND OF THE INVENTION It is an object of the present invention to provide a sleep-inducing toothpaste or mouth spray which includes sleep-inducing natural herbs and a natural hormone. It is a further object of the present invention to provide a sleep-inducing toothpaste which includes toothpaste base ingredients and natural herbs being Chamomile, Lemon Balm, Passion Flower, Valerian and the natural hormone Melatonin. SUMMARY OF THE INVENTION A toothpaste composition is provided for inducing sleep while simultaneously promoting intraoral cleanliness, which includes toothpaste base ingredients and at least one sleep-inducing natural herb or hormone. The sleep-inducing natural herbs and hormone are selected from the group consisting of the natural herbs Chamomile, Lemon Balm, Passion Flower, and Valerian, and the natural hormone Melatonin.
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation
    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
    [Show full text]
  • Paroxetine Shows No Effect on Drinking
    28 Addiction Psychiatry C LINICAL P SYCHIATRY N EWS • September 2007 Paroxetine Shows No E VIDENCE-BASED P SYCHIATRIC M EDICINE Effect on Drinking Abuse of Bupropion BY MICHELE G. SULLIVAN The patients’ average age was 29 The Problem caloric intake, or sleep. On self-rating scales, Mid-Atlantic Bureau years; 50% were male. At base- You work in one of America’s contemporary bupropion was perceived as an active drug only line, their mean score on the Lei- long-term psychiatric treatment centers, also as often as placebo. The investigators con- C HICAGO — Paroxetine can bowitz Social Anxiety Scale (LSAS) known as a state prison. Inmates who come to cluded, “It is unlikely that bupropion will give take the anxiety out of the drinker, was about 90, indicating severe so- outpatient appointments and complain of de- rise to [amphetaminelike] patterns of abuse but it cannot take the drinking out cial anxiety. Anxiety had its onset pressive symptoms frequently request bupro- among normals or among those predisposed of the anxious person. at age 12 years in these patients; pion (Wellbutrin). The history they provide is to psychostimulant abuse.” (The study came The drug did uncouple anxiety the use of alcohol to cope with speciously similar: “It’s the only antidepressant from the Baylor College of Medicine, the and drinking in patients who use symptoms followed about a that’s ever worked.” You start to inquire about Houston Veterans Administration Medical alcohol to cope with severe gener- decade later. They were moder- how this medication is used in the prison Center, and the Burroughs Wellcome Research alized social anxiety, Dr.
    [Show full text]
  • Low-Dose Doxepin for Treatment of Pruritus in Patients on Hemodialysis
    DIALYSIS Low-Dose Doxepin for Treatment of Pruritus in Patients on Hemodialysis Fatemeh Pour-Reza-Gholi,1 Alireza Nasrollahi,2 Ahmad Firouzan,1 Ensieh Nasli Esfahani,1 Farhat Farrokhi3 1Department of Nephrology, Introduction. Pruritus is one of the frequent discomforting Shaheed Labbafinejad complications in patients with end-stage renal disease. We Medical Center & Urology and prospectively evaluated the effectiveness of doxepin, an H1-receptor Nephrology Research Center, antagonist of histamine, in patients with pruritus resistant to Shaheed Beheshti Medical University, Tehran, Iran conventional treatment. 2Department of Nephrology, Materials and Methods. A randomized controlled trial with a Shohada-e-Tajrish Hospital, crossover design was performed on 24 patients in whom other Shaheed Beheshti Medical etiologic factors of pruritus had been ruled out. They were assigned University, Tehran, Iran into 2 groups and received either placebo or oral doxepin, 10 mg, 3Urology and Nephrology Research Center, Shaheed twice a day for 1 week. After a 1-week washout period, the 2 groups Beheshti Medical University, were treated conversely. Subjective outcome was determined by Tehran, Iran asking the patients described their pruritus as completely improved, relatively improved, or remained unchanged/worsened. Keywords. pruritus, doxepin, Results. Complete resolution of pruritus was reported in end-stage renal disease, 14 patients (58.3%) with doxepin and 2 (8.3%) with placebo dialysis (P < .001). Relative improvement was observed in 7 (29.2%) and 4 (16.7%), respectively. Overall, the improving effect of doxepin on Original Paper pruritus was seen in 87.5% of the patients. Twelve patients (50.0%) complained of drowsiness that alleviated in all cases after 2 days in average.
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]